Chayasirisobhon Sirichai
Department of Neurology, Kaiser Permanente Medical Center, Anaheim, CA 92807, USA.
Headache. 2006 May;46(5):788-93. doi: 10.1111/j.1526-4610.2006.00454.x.
To evaluate the potential benefit of a pine bark extract and antioxidant vitamin combination product in the treatment of migraine headache.
This was an uncontrolled preliminary study to investigate the potential of an antioxidant formulation as therapy for migraine headache.
Twelve patients with a long-term history of migraine with and without aura who had failed to respond to multiple treatments with beta-blockers, antidepressants, anticonvulsants, and 5-hydroxytryptamine receptor agonists were selected for the study. They were treated with 10 capsules of an antioxidant formulation of 120 mg pine bark extract, 60 mg vitamin C, and 30 IU vitamin E in each capsule daily for 3 months. Following enrollment patients completed a migraine disability assessment (MIDAS) questionnaire to give a baseline measure of migraine impact on work, school, domestic, and social activities over the previous 3 months. Patients were then treated for 3 months with the antioxidant formulation while continuing to receive existing pharmacologic medications. A second MIDAS was given at the conclusion of the treatment period.
There was a significant mean improvement in MIDAS score of 50.6% for the 3-month treatment period compared with the 3 months prior to baseline (P < .005). The treatment was also associated with significant reductions in number of headache days and headache severity score. Mean number of headache days was reduced from 44.4 days at baseline (95% CI 28.9 to 59.8) to 26.0 days (95% CI 5.3 to 46.7; P < .005) after 3 months' therapy and mean headache severity was reduced from 7.5 of 10 (95% CI 6.7 to 8.4) to 5.5 (95% CI 4.1 to 7.0; P < .005).
These data suggest that the antioxidant therapy used in this study may be beneficial in the treatment of migraine possibly reducing headache frequency and severity. Further clinical investigation into the efficacy of antioxidant as therapy for chronic migraine is warranted.
评估一种松树皮提取物与抗氧化维生素组合产品在治疗偏头痛方面的潜在益处。
这是一项非对照性初步研究，旨在调查一种抗氧化制剂作为偏头痛治疗方法的潜力。
选取12例有或无先兆的长期偏头痛患者，这些患者对β受体阻滞剂、抗抑郁药、抗惊厥药和5-羟色胺受体激动剂的多种治疗均无反应。他们每天服用10粒胶囊的抗氧化制剂，每粒胶囊含120毫克松树皮提取物、60毫克维生素C和30国际单位维生素E，持续3个月。入组后，患者完成一份偏头痛残疾评估（MIDAS）问卷，以给出偏头痛在过去3个月对工作、学校、家庭和社交活动影响的基线测量值。然后患者用抗氧化制剂治疗3个月，同时继续服用现有的药物。在治疗期结束时进行第二次MIDAS评估。
与基线前的3个月相比，3个月治疗期的MIDAS评分平均显著改善了50.6%（P < .005）。该治疗还与头痛天数和头痛严重程度评分的显著降低相关。治疗3个月后，平均头痛天数从基线时的44.4天（95%可信区间28.9至59.8）降至26.0天（95%可信区间5.3至46.7；P < .005），平均头痛严重程度从10分中的7.5分（95%可信区间6.7至8.4）降至5.5分（95%可信区间4.1至7.0；P < .005）。
这些数据表明，本研究中使用的抗氧化疗法可能对偏头痛治疗有益，可能会降低头痛频率和严重程度。有必要对抗氧化剂作为慢性偏头痛治疗方法的疗效进行进一步的临床研究。
